RPS6 and gastric cancer: To explore the underlying mechanisms, we found that HZ-A-018 was much more efficient in the suppression of AKT/S6 pathway than ACP-196, which probably contributed to the anti-cancer activity of HZ-A-018 in gastric cancer (Su et al., 2021).